| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:21432428 | IVR | 20 % | 20 % | Decreased 5-HIAA/serotonin (5-HT) ratio | Neurological endocrine-mediated perturbations |
| IVR | 10 % | 10 % | Altered DOPAC/DA ratio | Neurological endocrine-mediated perturbations | |
| IVR | 10 % | 10 % | Decreased 5-HIAA/serotonin (5-HT) ratio | Neurological endocrine-mediated perturbations | |
| IVR | 5 % | 5 % | Altered DOPAC/DA ratio | Neurological endocrine-mediated perturbations | |
| IVR | 20 % | 20 % | Altered DOPAC/DA ratio | Neurological endocrine-mediated perturbations | |
| IVR | 5 % | 5 % | Decreased 5-HIAA/serotonin (5-HT) ratio | Neurological endocrine-mediated perturbations | |
| PMID:21463340 | IVR | 1000 mg/kg | 1000 mg/kg | Affects developmental process | Developmental endocrine-mediated perturbations |
| IVR | 1000 mg/kg | 1000 mg/kg | Affects neuronal signaling | Neurological endocrine-mediated perturbations | |
| IVR | 2000 mg/kg | 2000 mg/kg | Affects neuronal signaling | Neurological endocrine-mediated perturbations | |
| IVR | 2000 mg/kg | 2000 mg/kg | Affects developmental process | Developmental endocrine-mediated perturbations | |
| IVR | 500 mg/kg | - | No significant effects observed | - | |
| PMID:2318350 | IVR | 5 % | 5 % | Induce behavioral changes | Neurological endocrine-mediated perturbations |
| PMID:37994192 | IVR | 3 mg/kg/day | 3 mg/kg/day | Decreased body weights | Metabolic endocrine-mediated perturbations |
| IVR | 3 mg/kg/day | 3 mg/kg/day | Decreased LDL levels | Metabolic endocrine-mediated perturbations | |
| IVR | 3 mg/kg/day | 3 mg/kg/day | Decrease LDL/HDL ratio | Metabolic endocrine-mediated perturbations | |
| IVR | 3 mg/kg/day | 3 mg/kg/day | Oxidative stress in pancreas | Metabolic endocrine-mediated perturbations | |
| IVR | 3 mg/kg/day | 3 mg/kg/day | Elevated insulin levels | Metabolic endocrine-mediated perturbations | |
| IVR | 3 mg/kg/day | 3 mg/kg/day | Elevated glucose levels | Metabolic endocrine-mediated perturbations | |
| IVR | 3 mg/kg/day | 3 mg/kg/day | Altered adipogenesis | Metabolic endocrine-mediated perturbations | |
| IVR | 3 mg/kg/day | 3 mg/kg/day | Affects insulin signaling | Metabolic endocrine-mediated perturbations | |
| IVR | 3 mg/kg/day | 3 mg/kg/day | Causes insulin resistance | Metabolic endocrine-mediated perturbations | |
| IVR | 3 mg/kg/day | 3 mg/kg/day | Decreased leptin levels | Metabolic endocrine-mediated perturbations | |
| IVR | 3 mg/kg/day | 3 mg/kg/day | Altered adipocyte morphology | Metabolic endocrine-mediated perturbations | |
| IVR | 3 mg/kg/day | 3 mg/kg/day | Changes in morphology of adipose tissue | Metabolic endocrine-mediated perturbations | |
| IVR | 3 mg/kg/day | 3 mg/kg/day | Causes inflammation | Immunological endocrine-mediated perturbations | |
| IVR | 3 mg/kg/day | 3 mg/kg/day | Increased VLDL levels | Metabolic endocrine-mediated perturbations | |
| IVR | 3 mg/kg/day | 3 mg/kg/day | Changes in morphology of pancreas | Metabolic endocrine-mediated perturbations | |
| IVR | 3 mg/kg/day | 3 mg/kg/day | Increased HDL levels | Metabolic endocrine-mediated perturbations | |
| IVR | 3 mg/kg/day | 3 mg/kg/day | Increased cholesterol levels | Metabolic endocrine-mediated perturbations | |
| IVR | 3 mg/kg/day | 3 mg/kg/day | Increased triglycerides level | Metabolic endocrine-mediated perturbations | |
| PMID:611632 | IVR | 1.24 mg/kg/day | 1.24 mg/kg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations |
| IVR | 0.62 mg/kg/day | - | No significant effects observed | - |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.